Enlivex ENLV
NASDAQ ENLV
$1.45 -0.05 (-3.34%)
As of: Aug 21, 2026 · 9:49 AM EDT

Enlivex (ENLV) EBITDA Margin (2022 - 2025)

Enlivex (ENLV) posted quarterly EBITDA Margin of 92.54% for Q1 2025, up 334.0% year-over-year from 21.32% in Q1 2024, and up 283.59% quarter-over-quarter from 50.4% in Q4 2024.

Enlivex (ENLV) EBITDA Margin (2022 - 2025) Analysis & Trends

Enlivex's EBITDA Margin history runs 4 years deep, the most recent figure standing at 92.54% for Q1 2025.

  • In Q1 2025, EBITDA Margin rose 334.0% year-over-year to 92.54%; the TTM figure through Mar 2025 stood at 62.08% (up 194867.0% YoY), while the FY2024 annual figure was 43.01%, down 5667.0% from the prior year.
  • EBITDA Margin for Q1 2025 stood at 92.54%, up from 50.4% in the prior quarter.
  • The five-year high for EBITDA Margin was 92.54% in Q1 2025, with the low at 50.4% in Q4 2024.
  • The 4-year median for EBITDA Margin is 83.06% (2023), against an average of 41.71%.
  • The sharpest annual moves came in 2023 and 2024: EBITDA Margin jumped 1053 bps in 2023, then tumbled 320 bps in 2024.
  • Enlivex's EBITDA Margin stood at 77.79% in 2022, then sank by 161 bps to 47.2% in 2023, then fell by 7 bps to 50.4% in 2024, then surged by 284 bps to 92.54% in 2025.
  • Business Quant data shows ENLV's EBITDA Margin at 92.54% in Q1 2025, 50.4% in Q4 2024, and 89.19% in Q1 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Vertex Pharmaceuticals 138.04 Bn 130.18 Bn 2.84 Bn 37.40%
2 Regeneron Pharmaceuticals 85.98 Bn 77.98 Bn 3.93 Bn 30.15%
3 Argenx Se 64.37 Bn 59.19 Bn 1.37 Bn 32.54%
4 Moderna 57.67 Bn 52.53 Bn 52.00 Mn -562.07%
5 BeOne Medicines 41.94 Bn 36.84 Bn 1.53 Bn 19.06%
6 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 17.93%
7 BioNTech SE 27.75 Bn 9.35 Bn 668.28 Mn -35.57%
8 Insmed 27.24 Bn 26.08 Bn 358.27 Mn -0.36%
9 Royalty Pharma 27.03 Bn 26.20 Bn - 19.75%
10 Enlivex 4.42 Mn -1.34 Mn - -

Historic Data

Download Data
DateValue
Mar 31, 2025 92.54%
Dec 31, 2024 -50.40%
Mar 31, 2024 89.19%
Dec 31, 2023 -47.20%
Mar 31, 2023 88.32%
Mar 31, 2022 77.79%